Reaction Details Report a problem with these data
Target
MAP kinase-activated protein kinase 2
Ligand
BDBM16316
Substrate
n/a
Meas. Tech.
ChEMBL_429706 (CHEMBL904280)
IC50
>10000±n/a nM
Citation
 Leftheris, K; Ahmed, G; Chan, R; Dyckman, AJ; Hussain, Z; Ho, K; Hynes, J; Letourneau, J; Li, W; Lin, S; Metzger, A; Moriarty, KJ; Riviello, C; Shimshock, Y; Wen, J; Wityak, J; Wrobleski, ST; Wu, H; Wu, J; Desai, M; Gillooly, KM; Lin, TH; Loo, D; McIntyre, KW; Pitt, S; Shen, DR; Shuster, DJ; Zhang, R; Diller, D; Doweyko, A; Sack, J; Baldwin, J; Barrish, J; Dodd, J; Henderson, I; Kanner, S; Schieven, GL; Webb, M The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J Med Chem 47:6283-91 (2004) [PubMed]  Article 
Target
Name:
MAP kinase-activated protein kinase 2
Synonyms:
MAP kinase-activated protein kinase 2 (MAPKAPK2) | MAP kinase-activated protein kinase 2 (MK2) | MAP kinase-activated protein kinase 2 (p38/MK2) | MAPK-Activated Protein Kinase 2 (MK2) | MAPK-activated protein kinase 2 | MAPK2_HUMAN | MAPKAP kinase 2 | MAPKAPK-2 | MAPKAPK2 | MK2
Type:
Serine/threonine-protein kinase
Mol. Mass.:
45579.87
Organism:
Homo sapiens (Human)
Description:
P49137
Residue:
400
Sequence:
MLSNSQGQSPPVPFPAPAPPPQPPTPALPHPPAQPPPPPPQQFPQFHVKSGLQIKKNAIIDDYKVTSQVLGLGINGKVLQIFNKRTQEKFALKMLQDCPKARREVELHWRASQCPHIVRIVDVYENLYAGRKCLLIVMECLDGGELFSRIQDRGDQAFTEREASEIMKSIGEAIQYLHSINIAHRDVKPENLLYTSKRPNAILKLTDFGFAKETTSHNSLTTPCYTPYYVAPEVLGPEKYDKSCDMWSLGVIMYILLCGYPPFYSNHGLAISPGMKTRIRMGQYEFPNPEWSEVSEEVKMLIRNLLKTEPTQRMTITEFMNHPWIMQSTKVPQTPLHTSRVLKEDKERWEDVKEEMTSALATMRVDYEQIKIKKIEDASNPLLLKRRKKARALEAAALAH
  
Inhibitor
Name:
BDBM16316
Synonyms:
3-({4-[(2,2-dimethylpropyl)(methyl)amino]-6-(4-methyl-1,4-diazepan-1-yl)-1,3,5-triazin-2-yl}amino)-N-methoxy-4-methylbenzamide | CHEMBL225088 | triaminotriazine aniline amide inhibitor, 1
Type:
Small organic molecule
Emp. Form.:
C24H38N8O2
Mol. Mass.:
470.6109
SMILES:
CONC(=O)c1ccc(C)c(Nc2nc(nc(n2)N2CCCN(C)CC2)N(C)CC(C)(C)C)c1
Structure:
Search PDB for entries with ligand similarity: